Skip to main content

Table 1 Patient characteristics (n = 161)

From: Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy

  Surgical margin 
CharacteristicsAll
(n = 161) (%)
< 1 mm
(n = 28) (%)
≥ 1 mm, <  2 mm
(n = 21) (%)
≥ 2 mm
(n = 112) (%)
P
Age, year
 Median (range)47.4 (25.4–87.3)51.7 (27.6–87.3)46.4 (25.4–68.5)46.9 (27.6–74.7) 
 Mean ± SD48.1 ± 11.051.7 ± 13.546.3 ± 10.147.5 ± 10.4 
  <  5096 (59.6)13 (46.4)12 (57.1)71 (63.4)0.254
  ≥ 5065 (40.4)15 (53.6)9 (42.9)41 (36.6) 
Tumour size
 T1 (≤ 2 cm)18 (11.2)3 (10.7)1 (4.8)14 (12.5)0.782
 T2 (>  2 cm, ≤ 5 cm)132 (82.0)24 (85.7)18 (85.7)90 (80.4) 
 T3 (>  5 cm)11 (6.8)1 (3.6)2 (9.5)8 (7.1) 
Lymph node status
 Negative34 (21.1)6 (21.4)5 (23.8)23 (20.5)0.944
 Positive127 (78.9)22 (78.6)16 (76.2)89 (79.5) 
Histological type
 IDC145 (90.1)22 (78.6)19 (90.5)104 (92.9)0.152
 IDC + DCIS12 (7.5)4 (14.3)1 (4.8)7 (6.2) 
 Others4 (2.5)2 (7.1)1 (4.8)1 (0.9) 
Histological grade
 in situ2 (1.3)1 (3.6)1 (5.0)0 (0)0.173
 I17 (11.3)4 (14.3)1 (5.0)12 (11.8) 
 II77 (51.3)16 (57.1)13 (65.0)48 (47.1) 
 III54 (36.0)7 (25.0)5 (25.0)42 (41.2) 
 Missing110110 
Intrinsic subtype
 Luminal53 (32.9)9 (32.1)11 (52.4)33 (29.5)0.379
 Luminal HER241 (25.5)8 (28.6)3 (14.3)30 (26.8) 
 HER221 (13.0)5 (17.9)3 (14.3)13 (11.6) 
 TNBC46 (28.6)6 (21.4)4 (19.0)36 (32.1) 
Chemotherapy
 Anthracycline-based33 (20.5)5 (17.9)7 (33.3)21 (18.8)0.427
 Taxane-based14 (8.7)2 (7.1)2 (9.5)10 (8.9) 
 Combined anthracycline and taxane65 40.4)10 (35.7)7 (33.3)48 (42.9) 
 HER2 targeting agent contained46 (28.6)9 (32.1)5 (23.8)32 (28.6) 
 Others3 (1.9)2 (7.1)0 (0)1 (0.9) 
Follow-up, month
Median (range)34.7 (5.3–118.9)23.5 (5.3–105.5)39.3 (7.7–105.6)35.8 (6.9–118.9) 
Mean ± SD44.9 ± 31.836.1 ± 29.549.3 ± 34.246.2 ± 31.9